Preclinical and translational research at VHIO focuses on establishing new ways to halt and revert the progression of highly aggressive tumors, including those affecting the breast, pancreas, colon, lung, and brain.

Considering the extensive inter- and intra-tumoral heterogeneity of human cancers, this is a complex challenge. To achieve this, we investigate novel anti-cancer therapeutic approaches tailored to each tumor type. We apply these therapies in increasingly faithful experimental models. Using these predictive models, we also anticipate the resistance of tumors to anti-cancer drugs.